Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib
Our results demonstrate that dapagliflozin not only enhances the antitumor efficacy of sunitinib against renal cell carcinoma but also alleviates sunitinib-induced cardiac toxicity in mice via modulation of the AMPKα-PPARα axis.
Authors
- Min Hu (ORCID: https://orcid.org/0000-0001-9433-9547)
- Shi‐Yu Huang (ORCID: https://orcid.org/0000-0002-3721-987X)
- Yujie Chen (ORCID: https://orcid.org/0000-0002-9905-9138)
- Jiachen Liu (ORCID: https://orcid.org/0000-0002-0263-3704)
- Lei Wang (ORCID: https://orcid.org/0000-0001-5349-6298)
- Zhi-yuan Chen (ORCID: https://orcid.org/0000-0002-9802-4208)
- Xiuheng Liu (ORCID: https://orcid.org/0000-0002-2633-9577)
- Zhiyuan Yao (ORCID: https://orcid.org/0000-0003-2912-1212)
Institutions
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-12-15
- DOI
- https://doi.org/10.1186/s12916-025-04576-z
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00